Dang, Chau <br/><br/>
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 2010 
 - 2982-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.26.5900  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Diarrhea--chemically induced<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Feasibility Studies<br/>Female<br/>Filgrastim<br/>Follow-Up Studies<br/>Gene Amplification<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Immunoenzyme Techniques<br/>In Situ Hybridization, Fluorescence<br/>Lapatinib<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Pilot Projects<br/>Polyethylene Glycols<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--genetics<br/>Recombinant Proteins<br/>Survival Rate<br/>Trastuzumab<br/>Treatment Outcome